These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 15153441)

  • 1. PET in the diagnosis of neuroendocrine tumors.
    Sundin A; Eriksson B; Bergström M; Långström B; Oberg K; Orlefors H
    Ann N Y Acad Sci; 2004 Apr; 1014():246-57. PubMed ID: 15153441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies.
    Eriksson B; Bergström M; Orlefors H; Sundin A; Oberg K; Långström B
    Q J Nucl Med; 2000 Mar; 44(1):68-76. PubMed ID: 10932603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.
    Orlefors H; Sundin A; Ahlström H; Bjurling P; Bergström M; Lilja A; Långström B; Oberg K; Eriksson B
    J Clin Oncol; 1998 Jul; 16(7):2534-41. PubMed ID: 9667275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear imaging of neuroendocrine tumours.
    Sundin A; Garske U; Orlefors H
    Best Pract Res Clin Endocrinol Metab; 2007 Mar; 21(1):69-85. PubMed ID: 17382266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of PET in localization of neuroendocrine and adrenocortical tumors.
    Eriksson B; Bergström M; Sundin A; Juhlin C; Orlefors H; Oberg K; Långström B
    Ann N Y Acad Sci; 2002 Sep; 970():159-69. PubMed ID: 12381551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography (PET) in neuroendocrine gastrointestinal tumors.
    Eriksson B; Bergström M; Lilja A; Ahlström H; Långström B; Oberg K
    Acta Oncol; 1993; 32(2):189-96. PubMed ID: 7686763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
    Koopmans KP; Neels OC; Kema IP; Elsinga PH; Sluiter WJ; Vanghillewe K; Brouwers AH; Jager PL; de Vries EG
    J Clin Oncol; 2008 Mar; 26(9):1489-95. PubMed ID: 18349401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of 11C-5-hydroxy-tryptophan positron emission tomography in neuroendocrine tumor diagnosis and management: experience from one center.
    Nikolaou A; Thomas D; Kampanellou C; Alexandraki K; Andersson LG; Sundin A; Kaltsas G
    J Endocrinol Invest; 2010 Dec; 33(11):794-9. PubMed ID: 20332708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.
    Sundin A; Eriksson B; Bergström M; Bjurling P; Lindner KJ; Oberg K; Långström B
    Nucl Med Biol; 2000 Jan; 27(1):33-41. PubMed ID: 10755643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear medicine imaging of neuroendocrine tumours.
    Bombardieri E; Maccauro M; De Deckere E; Savelli G; Chiti A
    Ann Oncol; 2001; 12 Suppl 2():S51-61. PubMed ID: 11762353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of (18) F-FDOPA PET/CT imaging in endocrinology.
    Santhanam P; Taïeb D
    Clin Endocrinol (Oxf); 2014 Dec; 81(6):789-98. PubMed ID: 25056984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carbidopa pretreatment improves image interpretation and visualisation of carcinoid tumours with 11C-5-hydroxytryptophan positron emission tomography.
    Orlefors H; Sundin A; Lu L; Oberg K; Långström B; Eriksson B; Bergström M
    Eur J Nucl Med Mol Imaging; 2006 Jan; 33(1):60-5. PubMed ID: 16184369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.
    Orlefors H; Sundin A; Garske U; Juhlin C; Oberg K; Skogseid B; Langstrom B; Bergstrom M; Eriksson B
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3392-400. PubMed ID: 15755858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
    Carollo A; Papi S; Grana CM; Mansi L; Chinol M
    Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of positron emission tomography (PET) in diagnostics of gastroenteropancreatic neuroendocrine tumours (GEP NET).
    Junik R; Drobik P; Małkowski B; Kobus-Błachnio K
    Adv Med Sci; 2006; 51():66-8. PubMed ID: 17357280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic neuroendocrine tumors: diagnosis with PET.
    Ahlström H; Eriksson B; Bergström M; Bjurling P; Långström B; Oberg K
    Radiology; 1995 May; 195(2):333-7. PubMed ID: 7724749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.
    Neels OC; Koopmans KP; Jager PL; Vercauteren L; van Waarde A; Doorduin J; Timmer-Bosscha H; Brouwers AH; de Vries EG; Dierckx RA; Kema IP; Elsinga PH
    Cancer Res; 2008 Sep; 68(17):7183-90. PubMed ID: 18757434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
    Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
    J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.